Vyome Holdings, Inc. (NASDAQ:HIND) Given Average Rating of “Hold” by Brokerages

Shares of Vyome Holdings, Inc. (NASDAQ:HIND) have received a consensus rating of “Hold” from the five research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $15.00.

Several analysts have commented on HIND shares. Litchfield Hills Research started coverage on Vyome in a report on Monday, May 4th. They issued a “buy” rating for the company. Zacks Research upgraded Vyome to a “hold” rating in a report on Wednesday, May 6th. Finally, Weiss Ratings upgraded Vyome from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st.

Institutional Trading of Vyome

A hedge fund recently bought a new stake in Vyome stock. Millennium Management LLC bought a new position in shares of Vyome Holdings, Inc. (NASDAQ:HIND) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 45,144 shares of the company’s stock, valued at approximately $155,000. Millennium Management LLC owned 0.80% of Vyome as of its most recent filing with the SEC. 22.06% of the stock is currently owned by institutional investors and hedge funds.

Vyome Price Performance

HIND opened at $2.19 on Tuesday. The stock has a market capitalization of $15.37 million, a price-to-earnings ratio of -0.18 and a beta of 1.48. The business has a 50-day moving average of $2.16 and a two-hundred day moving average of $2.93. Vyome has a 12 month low of $1.75 and a 12 month high of $18.60.

Vyome (NASDAQ:HIND) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.15) EPS for the quarter. The business had revenue of $0.03 million during the quarter. Vyome had a negative net margin of 270.58% and a negative return on equity of 203.92%. Equities research analysts anticipate that Vyome will post -0.6 earnings per share for the current year.

About Vyome

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.